Management of Anastrozole-Induced Neutropenia

Assessment and Management

For patients experiencing neutropenia due to anastrozole therapy, discontinue the medication and initiate granulocyte colony-stimulating factor (G-CSF) therapy until neutrophil recovery, then consider alternative hormonal therapy options, as recommended by the American Society of Clinical Oncology 1, 2
Monitor complete blood counts with differential to track neutrophil levels and recovery, and assess for signs of infection, particularly fever, which requires immediate intervention, according to the Infectious Diseases Society of America 2, 3, 4
Consider G-CSF (filgrastim) at 5 μg/kg/day subcutaneously until neutrophil recovery (ANC > 1,000/mcL), as suggested by the National Comprehensive Cancer Network 1
Hospitalize patients with febrile neutropenia (temperature ≥38.0°C) for immediate intervention, and obtain blood cultures and other relevant cultures before starting antibiotics, as recommended by the American College of Physicians 3
Initiate empiric broad-spectrum antibiotics within 2 hours of presentation, and consider an antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, or carbapenem) as monotherapy, according to the Clinical Infectious Diseases guidelines 2, 4

Consider antibacterial prophylaxis with fluoroquinolone (levofloxacin or ciprofloxacin 500 mg daily) if ANC < 500/mcL, and antifungal prophylaxis with fluconazole 400 mg daily if neutropenia is expected to be prolonged, as recommended by the Journal for ImmunoTherapy of Cancer 1, 6
Continue prophylaxis until ANC recovers to > 500/mcL, and monitor blood counts frequently until recovery, as suggested by the Leukemia guidelines 1, 5
After neutrophil recovery, consider alternative hormonal therapy options for breast cancer treatment, including different aromatase inhibitors (exemestane or letrozole), selective estrogen receptor modulators (tamoxifen), or fulvestrant (estrogen receptor antagonist), as recommended by the National Comprehensive Cancer Network 7

Monitor blood counts weekly until ANC normalizes, and after recovery and initiation of alternative therapy, monitor blood counts every 2 weeks for the first month, then monthly for 3 months, as suggested by the Leukemia guidelines 5
Educate patients about reporting fever or signs of infection promptly, and provide long-term monitoring every 3 months for the first year after the neutropenic episode, according to the Clinical Infectious Diseases guidelines 4, 5